RxDoctor Payments Data

Venkatesh Reddy, MD

Nephrology · Longview, TXNPI 1891750840

Payments from drug & device makers

$1,646in general payments, 2019–2025

Across 86 payments — averaging $19.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$285
  • Amgen$244
  • Mallinckrodt Hospital Products Inc.$136
  • Akebia Therapeutics Inc$114
  • Boehringer Ingelheim$109
  • Calliditas Therapeutics US Inc.$102
  • plus $656 from 11 others

What the payments were for

  • Food & beverage$1,62599%
  • Education$201%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,646 in reported general payments places this provider in the 45th percentile of 1,070 nephrology providers in Texas.

See all nephrology providers in Texas

Medicare billing

Part B allowed, 2024
$275,034
Medicare patients
665
Services billed
2,408

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Sevelamer Carbonate169$41,023
VelphoroSucroferric Oxyhydroxide13$40,558
JardianceEmpagliflozin30$21,933
Tolvaptan11$19,800
FarxigaDapagliflozin Propanediol11$10,777
LokelmaSodium Zirconium Cyclosilicate18$8,604
EliquisApixaban12$8,463
Calcium Acetate70$6,125
Nifedipine ErNifedipine146$3,119
Midodrine Hcl40$1,383
Hydralazine Hcl163$1,349
Paricalcitol21$1,294
Potassium Chloride105$1,194
Megestrol Acetate23$1,066
Lidocaine-PrilocaineLidocaine/Prilocaine67$993

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Fresenius USA Marketing, Inc.Velphoro$35$40,55813 claims
Boehringer IngelheimJardiance$109$21,93330 claims
AstraZenecaFarxiga, Lokelma$285$19,38129 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 1,070 nephrology providers in Texas.

Other nephrology in Longview

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →